Charcot-Marie-Tooth Association

CMTA Headlines:

The 8th Annual CMTA Gala

Please join us for the 8th Annual CMTA Gala at the Essex House on Central Park South in Manhattan on October 24 from 6:30 to 9:30 p.m. Guest speakers Christina Baker Kline and Dr. Michael E. Shy will guide you through the past, present and future of CMT and the real hope that exists for treatments for the 2.8 million people living with it. Read more…

Fighting for Claire and Her Generation

Russ Mitchell talks for a living. He’s a sportscaster. But until recently he didn’t talk about his CMT with anyone outside his family. That changed in a big way on September 1, when he added his voice to the chorus of voices spreading the word about CMT for Awareness Month. Read his story…

MDA and CMTA Fund Grant to Study Gene Therapy in Charcot-Marie-Tooth Disease

March 17 – The Muscular Dystrophy Association and the Charcot-Marie-Tooth Association (CMTA) today announced a research grant totaling $119,999 to Kleopas Kleopa, M.D., for a study on the effectiveness of a gene therapy approach in CMT1X, the second most common form of Charcot-Marie-Tooth disease (CMT). Read more …

Stand to End CMT: Join the Movement

Julianna Snow, age five, passed away this summer from CMT. She was a huge inspiration for Stand to End CMT, a movement created to raise funds for treatment, and ultimately a cure, for CMT.

What is CMT?

Charcot-Marie-Tooth, or CMT, is the most commonly inherited peripheral neuropathy and affects an estimated 2.8 million people.

Find Your Local Branch

The CMTA has over 80 Branches across North America to support people with CMT, raise awareness, and fund research. Connect with your nearest Branch today!

Fundraise to End CMT

Without fundraising and community volunteers, the CMTA would not be the leading force in CMT Research that it is today. Are you ready to make an impact?

Shop Our Store

Visit our store to see some of the most fun and fashionable ways to raise awareness!

The CMTA’s STAR (Strategy to Accelerate Research)

The CMTA’s vision is a world where patients with CMT neuropathies have therapies available to them to manage or modify their disease. That vision is poised to become reality as STAR pushes the research forward at an ever-increasing speed.

STAR – Disease Project Team Updates

The CMTA’s research is done in teams consisting of academic labs and clinical centers sponsored by the CMTA (STAR members), working together and with alliance partners in consortium team efforts. STAR Teams are sponsored by the CMTA via a rapid process of expert review, following invitation of proposals for targeted translational efforts. All sponsorship aims to directly aid the advancement of CMT therapies.